Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729183 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13567846 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30325554 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2166676 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30325540 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2166680 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL376043 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2166686 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL376665 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL10130022 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137184-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8138181-B2 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2137184-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008124323-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | SMN1; SMN2 3711/4885NPC1 3848/4885RAB9A 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.